<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430102</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00022390</org_study_id>
    <nct_id>NCT03430102</nct_id>
  </id_info>
  <brief_title>Indicor Validation</brief_title>
  <official_title>Validation of the Indicor Device in Identifying Elevated Left Ventricular End Diastolic Pressure LVEDP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vixiar Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vixiar Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to repeat an initial training set study conducted at Johns Hopkins
      Medical Center, comparing a new investigational device, Indicor, a non-invasive tool for
      estimating left ventricular end diastolic pressure (LVEDP), to the gold standard, invasively
      measured LVEDP via direct measurement via left heart catheterization. The study is divided
      into an initial training set, followed by the validation set which is designed to support an
      FDA 510(k) submission and validate the final algorithm. Patients will be enrolled who are
      scheduled to undergo a cardiac catheterization and will be asked to perform three tests with
      the Indicor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are scheduled to undergo a left heart cardiac catheterization for direct measure
      of left ventricular end diastolic pressure (LVEDP) as part of routine care will be asked to
      participate. Investigators will take non-invasive measures of LVEDP using the Indicor device,
      repeated at three time points before and after the catheterization procedure. The Indicor
      indirectly measures LVEDP by calculating a value from finger photoplethysmography (PPG)
      waveforms that will be recorded while the patient performs a Valsalva maneuver.

      Participants baseline characteristics will be gathered from the electronic medical record,
      including history of coronary artery disease, heart failure, hypertension, diabetes, or lung
      disease; list of blood pressure medications; serum markers of kidney function; and
      echocardiogram measurements including ejection fraction. These parameters will be used to
      assess relevance to the calculation of LVEDP by Indicor.

      The first Indicor measure will be conducted before the catheterization procedure. PPG probes
      will be attached to participants' first or second finger. Participants will be asked to
      strain as if having a bowel movement (Valsalva maneuver) for 10 seconds. Participants will
      blow into a pressure transducer that measures and displays the pressure of their effort. The
      Indicor device will acquire 3 successful efforts.

      During the cardiac catheterization, while the pressure transducer used by the clinical team
      to measure LVEDP is in the aorta, the Valsalva testing will be repeated. The device will
      again acquire 3 successful efforts. This will allow investigators to determine how well the
      amplitude changes of the PPG signal during Valsalva maneuver reflect the amplitude changes of
      central arterial pressure during the Valsalva maneuver. According to experienced
      catheterization cardiologists, this set of tests will not add significant risk to the
      procedure. This second set of tests may not be performed in all participants.

      Immediately after the cardiac catheterization, while the patient is still on the
      catheterization table, the Valsalva testing will be repeated. The device will again acquire 3
      successful efforts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Anticipated">July 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>C-LVEDP</measure>
    <time_frame>During patients scheduled left heart cardiac catheterization</time_frame>
    <description>Specificity of Calculated LVEDP (C-LVEDP) in identifying invasively Measured LVEDP (M-LVEDP) &gt; 20 mmHg</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>LeftHeartCath</arm_group_label>
    <description>Patients scheduled for LV catheterization for direct measurement of LVEDP</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Indicor</intervention_name>
    <description>Calculation of LVEDP via analysis of PPG waveform with Valsalva</description>
    <arm_group_label>LeftHeartCath</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled to undergo cardiac catheterization as part of their routine care and
        clinically indicated
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Adult patients scheduled to undergo a left-heart catheterization that will include the
        measurement of left ventricular end-diastolic pressure (LVEDP)

        Exclusion Criteria:

          -  Weight &lt;88 pounds (40 kilograms)

          -  Atrial flutter or atrial fibrillation with an irregular ventricular response

          -  Significant atrial or ventricular ectopy

          -  History of paradoxical emboli

          -  Hypertrophic obstructive cardiomyopathy

          -  History of paradoxical emboli

          -  Known intracardiac shunt

          -  Known severe aortic valve stenosis or known severe mitral valve stenosis

          -  History of embolic cerebrovascular accident

          -  Clinically unstable

          -  Uncontrolled hypertension (systolic BP &gt;160 mmHg or diastolic BP&gt; 100 mmHg)

          -  Hypotension (systolic BP &lt;90 mmHg)

          -  Symptomatic bradycardia

          -  Known cholesterol emboli

          -  Poor LV function with known LV thrombus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Silber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Miller, PhD</last_name>
    <phone>(856) 279-1227</phone>
    <email>tmiller@vixiar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William Lawson, MD</last_name>
    <phone>(631) 444-4000</phone>
    <email>William.Lawson@stonybrookmedicine.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Christiana Care</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sourin Banerji, MD</last_name>
      <phone>302-733-4761</phone>
      <email>Sourin.Banerji@ChristianaCare.org</email>
    </contact>
    <contact_backup>
      <last_name>Jean Willis, BSN</last_name>
      <phone>(302) 733-4761</phone>
      <email>jwillis@christianacare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sourin Banerji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Syed A Hamid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth J Tenzler Stein, BSN</last_name>
      <phone>631-444-3309</phone>
      <email>Ruth.Tenzler@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>William Lawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster General Health</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay M Knepper, RN</last_name>
      <phone>717-544-1777</phone>
      <email>kmkneppe@LGHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Clayton-Yost, BSHA</last_name>
      <phone>717-544-1777</phone>
      <phone_ext>76417</phone_ext>
      <email>Lclayton-yost2@LGHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rahul Jhaveri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gilotra NA, Tedford RJ, Wittstein IS, Yenokyan G, Sharma K, Russell SD, Silber HA. Usefulness of Pulse Amplitude Changes During the Valsalva Maneuver Measured Using Finger Photoplethysmography to Identify Elevated Pulmonary Capillary Wedge Pressure in Patients With Heart Failure. Am J Cardiol. 2017 Sep 15;120(6):966-972. doi: 10.1016/j.amjcard.2017.06.029. Epub 2017 Jun 28.</citation>
    <PMID>28754567</PMID>
  </reference>
  <reference>
    <citation>Galiatsatos P, Win TT, Monti J, Johnston PV, Herzog W, Trost JC, Hwang CW, Fridman GY, Wang NY, Silber HA. Usefulness of a Noninvasive Device to Identify Elevated Left Ventricular Filling Pressure Using Finger Photoplethysmography During a Valsalva Maneuver. Am J Cardiol. 2017 Apr 1;119(7):1053-1060. doi: 10.1016/j.amjcard.2016.11.063. Epub 2017 Jan 5.</citation>
    <PMID>28185634</PMID>
  </reference>
  <reference>
    <citation>Silber HA, Trost JC, Johnston PV, Maughan WL, Wang NY, Kasper EK, Aversano TR, Bush DE. Finger photoplethysmography during the Valsalva maneuver reflects left ventricular filling pressure. Am J Physiol Heart Circ Physiol. 2012 May 15;302(10):H2043-7. doi: 10.1152/ajpheart.00609.2011. Epub 2012 Mar 2.</citation>
    <PMID>22389389</PMID>
  </reference>
  <reference>
    <citation>Sharma GV, Woods PA, Lambrew CT, Berg CM, Pietro DA, Rocco TP, Welt FW, Sacchetti P, McIntyre KM. Evaluation of a noninvasive system for determining left ventricular filling pressure. Arch Intern Med. 2002 Oct 14;162(18):2084-8.</citation>
    <PMID>12374516</PMID>
  </reference>
  <reference>
    <citation>Gillard C, Henuzet C, Lallemand J, Moscariello A, Guillaume M, Van Meerhaeghe A. Operating characteristics of the Finapress system to predict elevated left ventricular filling pressure. Clin Cardiol. 2006 Mar;29(3):107-11.</citation>
    <PMID>16596832</PMID>
  </reference>
  <reference>
    <citation>Zema MJ. Bedside assessment of cardiac hemodynamics: role of the simple Valsalva maneuver. Am J Med. 2012 Aug;125(8):e13; author reply e15-6. doi: 10.1016/j.amjmed.2011.12.020.</citation>
    <PMID>22840672</PMID>
  </reference>
  <reference>
    <citation>Felker GM, Cuculich PS, Gheorghiade M. The Valsalva maneuver: a bedside &quot;biomarker&quot; for heart failure. Am J Med. 2006 Feb;119(2):117-22. Review.</citation>
    <PMID>16443410</PMID>
  </reference>
  <reference>
    <citation>Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989 Feb 10;261(6):884-8.</citation>
    <PMID>2913385</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

